Alex A. Adjei, MD, PhD | Authors

Articles

MEK Inhibitors

April 23, 2014

The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.